Download Investigational drug NX-1207

Nymox Pivotal Phase 3 Fexapotide (NX1207) BPH Extension Trial Successfully
Meets Primary Endpoint
Primary Endpoint AUA BPH Symptom Score
• Single injection results after median 42 months posttreatment (range 24 months to 65 months)
• Mean improvement 5.3 points (p<.025 vs placebo)
• First-line treatment with fexapotide mean improvement
7.16 points (p<.02 vs placebo)
BPH Improvement
AUA BPH Symptom Score
Patient Responder Rate
• Statistically significant higher proportion of long-term
improved patients in AUA BPH Symptom Score
(primary outcome variable) after a single injection in
fexapotide treated subjects (64%) vs controls (p<.005)
Nocturia
• Median 42 months post-single injection treatment
• Stabilization or improvement 87% (p<.03 vs placebo)
Surgery for BPH
• 1.7% in 2 years after 1-2 injections of
fexapotide (p<.02 vs placebo)
Fexapotide Lowered Cancer Risk
• Phase 2 US data showing reduced
progression of low grade prostate cancer in
fexapotide treated patients
• This is in contrast to elevated cancer risk for
some approved BPH oral medications
Nymox Fexapotide Advantages
• Safe drug with durable efficacy
• Office-based 1-2 minute injection
• Single painless injection: no sedation, no anesthesia
• No sexual side effects (commonly seen with older approved
BPH medications)
• No cardiovascular or hormonal side effects (commonly
seen with older approved BPH medications)
• Decreased cancer risk (Phase 2 data) (vs increased risk
seen with older approved BPH medications)
Nymox Fexapotide Safety Profile
Superior to BPH approved medications
• No sexual or cardiovascular side effects
• No hormonal side effects
• No increased risk of prostate cancer (decreased risk with
fexapotide, Phase 2)
Nymox Fexapotide Efficacy Profile
Highly durable effect:
• Single painless office injection with long-term benefit
• After a single injection with fexapotide, the majority of patients
in Phase 3 pivotal studies required no further oral medications
or surgery for up to 5.4 years (median 42 months).
• First-line single treatment after 3.5 years: 7.16 point mean
improvement